– CANADA, Montreal – Giiant Pharma Inc., a preclinical-stage biotech company developing gut-restricted drug therapeutics in gastroenterology, today announced the appointment of Dr. Marie Lindner to its Board as an independent director.
“We are privileged to have Marie joining our Board of Directors. Her appointment will be pivotal for the company growth,” said CEO, Maxime Ranger.
About Dr. Marie Lindner
Dr. Marie Lindner, a seasoned executive worked in various executive roles in the pharmaceutical, biotech, venture capital, start-up, and Medtech companies, spending over 30 years in multiple therapeutic areas, including gastroenterology.
“I am thrilled to join Giiant’s endeavor in advancing their lead program GT-2018 and to support them with their various development programs. I believe my background and expertise will be an effective complement to the company’s already strong R&D strategy and business development,” said Dr. Lindner.
Following an esteemed academic and medical career, Marie Lindner is active on several boards. She was most recently focused on finding new trends in science and medicine at Novartis, as Global Program Head, Strategic Partnerships Team.
About Giiant Pharma
Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrug, with improved drug tolerability and enhanced therapeutic effect.
For more information: https://giiant.com/en/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
